The Beauty Health Company (NASDAQ:SKIN) Receives Average Recommendation of "Reduce" from Analysts

The Beauty Health Company (NASDAQ:SKIN - Get Free Report) has been given a consensus rating of "Reduce" by the twelve analysts that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $6.50.

Several equities research analysts recently weighed in on SKIN shares. DA Davidson reiterated a "buy" rating and issued a $5.00 target price on shares of Beauty Health in a research note on Friday, March 15th. Stifel Nicolaus reiterated a "hold" rating and issued a $4.00 target price (up previously from $3.00) on shares of Beauty Health in a research note on Wednesday, March 13th. Canaccord Genuity Group increased their target price on shares of Beauty Health from $3.00 to $4.00 and gave the company a "hold" rating in a research note on Thursday, March 14th. TD Cowen increased their target price on shares of Beauty Health from $2.50 to $4.00 and gave the company a "market perform" rating in a research note on Wednesday, March 13th. Finally, Piper Sandler reiterated an "underweight" rating and issued a $3.00 target price (up previously from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th.

Beauty Health Stock Performance

Shares of NASDAQ:SKIN traded down $0.16 during midday trading on Friday, hitting $3.27. The company's stock had a trading volume of 1,625,266 shares, compared to its average volume of 1,599,430. The stock has a market capitalization of $403.62 million, a price-to-earnings ratio of -4.25 and a beta of 1.01. The stock's 50 day simple moving average is $3.65 and its 200 day simple moving average is $3.47. Beauty Health has a fifty-two week low of $1.35 and a fifty-two week high of $13.90. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07.

Beauty Health (NASDAQ:SKIN - Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. The company had revenue of $96.80 million for the quarter, compared to the consensus estimate of $87.22 million. During the same period last year, the business posted $0.03 earnings per share. The firm's revenue was down 1.3% compared to the same quarter last year. As a group, research analysts anticipate that Beauty Health will post -0.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SKIN. Point72 Asset Management L.P. bought a new position in shares of Beauty Health in the fourth quarter valued at approximately $7,089,000. Senvest Management LLC raised its stake in shares of Beauty Health by 30.8% in the third quarter. Senvest Management LLC now owns 8,937,381 shares of the company's stock valued at $53,803,000 after acquiring an additional 2,106,622 shares during the last quarter. Braidwell LP bought a new position in shares of Beauty Health in the third quarter valued at approximately $9,790,000. Norges Bank bought a new position in shares of Beauty Health in the fourth quarter valued at approximately $7,730,000. Finally, Vanguard Group Inc. raised its stake in shares of Beauty Health by 8.6% in the third quarter. Vanguard Group Inc. now owns 10,514,288 shares of the company's stock valued at $123,964,000 after acquiring an additional 830,141 shares during the last quarter. Institutional investors own 93.26% of the company's stock.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.